Abstract
Angiotensin converting enzyme inhibitors

Direct renin inhibitors
Aliskiren is a new antihypertensive that acts by inhibiting renin activity [25] [33] . [34] . Eplerenone is metabolized primarily by CYP3A4. Therefore, inhibitors of CYP3A4 including grapefruit juice should be avoided in patients taking this drug. [35] [37] . ARBs [38] and mineralocorticoid receptor blockers [39] 
Spironolactone is used in doses of 12.5 to 25 mg per day for hypertension and heart failure, and up to 100 to 400 mg per day in cases of primary hyperaldosteronism. Side effects include gynecomastia and impotence as a result of its anti-androgenic effect, and hyperkalaemia. The latter must be carefully monitored since many of the patients taking spironolactone are also on nonsteroidal anti-inflammatory drugs, ACEIs or ARBs, compounding the hyperkalemic effect, or are diabetic and may have chronic kidney disease. In fact the use of these agents in patients with eGFR lower than 40 ml/min. is associated with hyperkalaemia, often difficult to control. Eplerenone is used in doses of 25-50 mg per day since it is less powerful a drug than spironolactone. It does not have anti-androgenic effects, and accordingly has less adverse side effects. However it is just as able to induce hyperkalaemia, which must be monitored, especially in those patients taking other RAS inhibitors or non-steroidal anti-inflammatory drugs, or who have lower eGFR. In fact, with the increased use of mineralocorticoid receptor blockade especially in heart failure, hyperkalaemia has become a more frequently observed undesirable and even dangerous side effect in cardiovascular therapy
Endothelin receptor antagonists
Blockers of endothelin receptors may bind with high affinity to type A endothelin receptors (ETAR) and/or to type B endothelin receptors (ETBR)
Antihypertensive therapy and small artery structure
We and others have proposed the idea that to improve clinical outcome in hypertensive patients therapy must induce regression of vascular remodelling [40] . The failure to produce regression of vessel wall changes may explain the limited success in preventing hypertension-related coronary events when blood pressure-lowering is the sole therapeutic aim.
Several studies have examined the beneficial effects of antihypertensive agents on small artery structure. Angiotensin-converting enzyme inhibition with cilazapril [41, 42] or perindopril [43] normalized structure of gluteal subcutaneous small arteries from essential hypertensive patients. Similar results have more recently been demonstrated with other renin-angiotensin blockers, particularly the ARBs, which have corrected both small artery structure and endothelial function in patients with essential hypertension [44, 45] . Calcium channel blockade may also normalize small artery structure [46, 47] . In contrast, antagonism of ␤-adrenoceptors with atenolol appears ineffective in improving small artery structural abnormalities [39] [40] [41] [42] [43] [44] [45] .
Whether the reversal of structural abnormalities demonstrated in gluteal subcutaneous arteries will result in improved clinical outcome remains to be determined [37] . However, regression of structural and functional abnormalities of gluteal subcutaneous arteries from hypertensive patients may be associated with improved structure and function of other more critical vascular beds such as the coronary circulation, as shown by indirect measurements [48] [49] [50] . The prognostic importance of small artery remodelling has been demonstrated by a study that showed that greater remodelling (media to lumen ratio) of small arteries was associated to more frequent cardiovascular events in a cohort of hypertensive patients [51] . Interestingly, the beneficial effects of blockade of the RAAS on structural remodelling of small arteries of hypertensive patients are also found on vessels from high risk patients with type 2 diabetes mellitus [52, 53] .
Aldosterone is recognized as an agent that induces collagen deposition and remodelling in pathophysiological conditions [54] . Accordingly, it is not surprising that treatment of hypertensive patients with eplerenone, a selective mineralocorticoid receptor blocker, resulted in reduced stiffness of both large arteries [55] and small arteries [56] . Interestingly, in the latter study, neither remodelling of small arteries nor endothelial function was improved by treatment with eplerenone, although blood pressure was normalized. However, collagen deposition and the collagento-elastin ratio were reduced [56] .
Although blockade of the renin -angiotensin system would be expected to result in improved vascular structure through inhibition of the growth-promoting, pro-oxidative and pro-inflammatory action of Ang II [57] , it has been argued that correction of small artery remodelling occurs mainly as a result of vasodilatation [58] . Arguments in favour are the fact that vasoconstriction contributes to the mechanism of small artery remodelling [59] , and that changes in flow associated with different states of vasodilation modulate vascular remodelling [60] . This may explain the absence of correction of vascular remodelling found with agents such as atenolol [41] [42] [43] [44] [45] [46] [47] which induces peripheral vasoconstriction [61] .
As shown in Fig. 1 [63] . However, short-term treatment with enalapril or cilazapril failed to regress endothelial dysfunction measured in vivo [64, 65] . Treatment with ARBs corrected endothelial dysfunction [44, 45, 66] . Chronic calcium channel blockade also normalized endothelial function in one study [46] but not in another [47] . Interestingly, as with structural abnormalities, ␤-adrenoceptor blockade with atenolol did not improve endothelial function [40, 42, 44, 63] 
Effect of antihypertensive treatment on arterioles
Arterioles with lumen diameters smaller than 100 m are also an important site of vascular resistance [69] . As with small arteries, some arterioles undergo eutrophic remodelling in hypertension; for example, pial arterioles in stroke-prone spontaneously hypertensive rats, in which in fact this phenomenon was first described [70] . Regression of structural remodelling towards normal, similar to that found in small arteries, has been reported to occur in arterioles of the brain in stroke-prone spontaneously hypertensive rats under antihypertensive therapy with ACEIs [71] . Similarly to their effects on structure, ACEIs may be more effective than ␤-blockers in improving the impaired cerebral vasodilatation of chronic hypertension [72] . 
